ライフサイエンスコーパス: osteoclastic

1 severing, and capping protein essential for osteoclastic actin cytoskeletal organization.

2 T(H) 1 and T(H) 17 cells that have known pro-osteoclastic actions in the alveolar bone.

3 hanisms mediating commensal microbiota's pro-osteoclastic actions include altered marrow effector CD4

4 egulates actin cytoskeletal organization and osteoclastic activation remain largely unknown.

5 iodontal disease by leukocyte chemotaxis and osteoclastic activation.

6 -induced osteoblastic lesions and underlying osteoclastic activities.

7 inhibited inflammatory cell infiltration and osteoclastic activity (P <0.05).

8 mes were achieved, in part, by reductions in osteoclastic activity and a biasing of hematopoietic ste

9 Conversely, the aged SSC lineage promoted osteoclastic activity and myeloid skewing by haematopoie

10 at systemic melatonin treatment may decrease osteoclastic activity and reduce ABL in the model using

11 Bisphosphonates such as pamidronate inhibit osteoclastic activity and reduce bone resorption.

12 o disturbed and was accompanied by increased osteoclastic activity and reduced trabecular bone format

13 ment of cancers metastatic to bone decreases osteoclastic activity and tumor burden and also may acco

14 urden and also may account for the decreased osteoclastic activity associated with successful treatme

15 nfirm the presence of either osteoblastic or osteoclastic activity associated with the DFDBA particle

16 of osteopontin (OPN), which in turn enhances osteoclastic activity by up-regulating cathepsin K and M

17 Lastly, we find that osteoclastic activity contributes to the TGF-beta-induce

18 results from increased osteoblast-dependent osteoclastic activity due to decreased osteoprotegerin m

19 However, apparent osteoclastic activity in periodontitis subjects is assoc

20 Such an autocrine-paracrine loop may sustain osteoclastic activity in the face of an inhibitory Ca2+

21 matory cell infiltration in the gingivae and osteoclastic activity in the jaw bones.

22 tion secondary to increased osteoblastic and osteoclastic activity is the price paid for metabolic co

23 as well as enhanced urinary excretion of the osteoclastic activity marker dexoypyridinoline.

24 id, a bisphosphonate given for prevention of osteoclastic activity of bone metastasis, secondary to b

25 However, the osteoclastic activity of TRAF6 is blunted by its associa

26 In vivo studies also revealed high osteoclastic activity surrounding developing teeth in mi

27 led researchers to test agents that inhibit osteoclastic activity to prevent or halt the formation o

28 Osteoclastic activity was measured by tartrate-resistant

29 chment level was significantly improved, and osteoclastic activity was reduced in mice treated with M

30 periodontitis, periodontal wound healing and osteoclastic activity were compared among natural wound

31 oods reduced plasma levels of a biomarker of osteoclastic activity without affecting biomarkers of os

32 m phosphate, ionized calcium, increased bone osteoclastic activity, and lower free fetuin-A, plasma p

33 By reducing osteoclastic activity, bisphosphonates inhibit bone reso

34 nhibitor of CCR1 and in turn a suppressor of osteoclastic activity, osteolytic lesions, and disease b

35 f osteocyte death and correlated with strong osteoclastic activity.

36 loss specifically through the regulation of osteoclastic activity.

37 vastating bone disease mediated by increased osteoclastic activity.

38 and mature osteoblasts control the degree of osteoclastic activity.

39 level, resulting in decreased THP-1-derived osteoclastic activity.

40 ell system to investigate RANKL-driven THP-1 osteoclastic activity.

41 derived from the long bones showed increased osteoclastic activity.

42 The decrease in inflammation, osteoclastic and collagenase activity and increase in os

43 which facilitates tumor growth via enhanced osteoclastic and endothelial cell activity in bone marro

44 ze the balance between, and determinants of, osteoclastic and osteoblastic activity in stunted infant

45 hatase and osteocalcin were used to identify osteoclastic and osteoblastic activity, respectively.

46 sion, migration adhesion, and stimulation of osteoclastic and osteoblastic activity.

47 ted that it does lead to an increase in both osteoclastic and osteoblastic activity.

48 ifies a BM myeloid precursor population with osteoclastic and T cell-suppressive activity that is exp

49 nate immunity and G2 tumors with angiogenic, osteoclastic, and adipogenic activities as well as PPARg

50 lux (r = 0.944; n = 23; P < 0.0001), between osteoclastic beta-glucuronidase activity and net calcium

51 edium prostaglandin E(2) (PGE(2)) levels and osteoclastic beta-glucuronidase activity were determined

52 pe of global Shn3 KO mice, including reduced osteoclastic bone catabolism in vivo, indicating that Sh

53 microgravity by 170% (p = 0.004), indicating osteoclastic bone degeneration.

54 Osteoclastic bone degradation requires intimacy between

55 is characterized both by markedly increased osteoclastic bone destruction and severely impaired oste

56 homes in the bone marrow and induces massive osteoclastic bone destruction presumably by producing cy

57 elucidate the mechanism underlying extensive osteoclastic bone destruction.

58 Excessive osteoclastic bone erosion disrupts normal bone remodelin

59 that T cell-replete mice undergo significant osteoclastic bone loss after IL-7 administration, concur

60 y via the inhibition of defined mediators of osteoclastic bone remodeling (e.g. receptor activator of

61 in osteoblastic bone formation activity nor osteoclastic bone resorption activity in vivo.

62 s a key mechanism by which estrogen prevents osteoclastic bone resorption and bone loss.

63 increased ERFE expression, triggers profound osteoclastic bone resorption and bone loss.

64 and atorvastatin (ATV) are known to inhibit osteoclastic bone resorption and have been proposed to h

65 nflammatory bone loss through stimulation of osteoclastic bone resorption and inhibition of osteoblas

66 Metabolic acidosis induces osteoclastic bone resorption and inhibits osteoblastic b

67 thermore, PTHrP caused a coupled increase in osteoclastic bone resorption and new bone formation that

68 loma bone disease is caused by uncoupling of osteoclastic bone resorption and osteoblastic bone forma

69 e of tumor implantation profoundly inhibited osteoclastic bone resorption and prevented hypercalcemia

70 -9 signaling, resulting in the inhibition of osteoclastic bone resorption and prostate cancer bone me

71 The bone disease is mediated by increased osteoclastic bone resorption and suppressed bone formati

72 an aminobisphosphonate, is known to inhibit osteoclastic bone resorption and was proposed to have os

73 calcium in the milk, a process that involves osteoclastic bone resorption but also osteocytes and per

74 nes during osteoclastogenesis, and prevented osteoclastic bone resorption but did not impair osteobla

75 264.7 cells suggested that the inhibition of osteoclastic bone resorption by these compounds did not

76 DO2) is a heritable bone disease of impaired osteoclastic bone resorption caused by missense mutation

77 es associated with osteocytic osteolysis and osteoclastic bone resorption compared to WT males which

78 Osteoclastic bone resorption depends upon the cell's abi

79 oblasts takes advantage of the regulation of osteoclastic bone resorption exerted by osteoblasts.

80 Accelerated osteoclastic bone resorption has a central role in the p

81 ncreased recognition of factors that promote osteoclastic bone resorption in cancer patients led us t

82 The mimetic dampens osteoclastic bone resorption in vitro and in vivo.

83 tives that have potent inhibitory effects on osteoclastic bone resorption in vitro and that prevent o

84 teoblastic activity to match the increase in osteoclastic bone resorption induced by estrogen deficie

85 nd 100 microg/l), reversed the inhibition of osteoclastic bone resorption induced by high extracellul

86 It has been hypothesized that osteoclastic bone resorption is a critical component bef

87 Osteoclastic bone resorption is a prominent feature of p

88 position, whereas in modern humans extensive osteoclastic bone resorption is found in the same region

89 Increased osteoclastic bone resorption leads to periarticular eros

90 ata suggest that the actions of IFN-gamma on osteoclastic bone resorption may be mediated by its effe

91 nment of the tooth because of the failure of osteoclastic bone resorption on the coronal tooth surfac

92 Increased osteoclastic bone resorption plays a central role in the

93 Accelerated osteoclastic bone resorption plays a central role in the

94 sive loss of bone mass resulting from excess osteoclastic bone resorption relative to osteoblastic bo

95 itory effect of Pyk2(Y402F), suggesting that osteoclastic bone resorption requires both c-Src kinase

96 Osteoclastic bone resorption requires cell-matrix contac

97 arge enough shift in systemic pH to increase osteoclastic bone resorption seems untenable.

98 ortisol inhibits acid-induced, cell-mediated osteoclastic bone resorption through a decrease in osteo

99 he aryl hydrocarbon receptor (Ahr) to induce osteoclastic bone resorption through the activation of c

100 s process of osteoblastic bone formation and osteoclastic bone resorption to maintain normal bone mas

101 Osteoclastic bone resorption was more sensitive to the i

102 lly protected from osteocytic osteolysis and osteoclastic bone resorption when allowed to lactate or

103 ive phosvitin potently inhibited PTH-induced osteoclastic bone resorption with simultaneous new osteo

104 t can target bone loss mediated by excessive osteoclastic bone resorption without affecting osteoblas

105 rparts, HIV-1 transgenic rats undergo severe osteoclastic bone resorption, a consequence of an imbala

106 In most cases, hypercalcemia is due to osteoclastic bone resorption, and agents that inhibit or

107 ase of bone is based on giving inhibitors of osteoclastic bone resorption, and bisphosphonates are th

108 remodeling, osteoblastic bone formation, and osteoclastic bone resorption, mediated via the TSH recep

109 wn to enhance osteoblastogenesis and inhibit osteoclastic bone resorption, thus promoting tissue rege

110 osteoblastic bone formation and by increased osteoclastic bone resorption, we assessed whether oxidiz

111 ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption, whereas flurbiprofen at si

112 xamination revealed that ibandronate reduced osteoclastic bone resorption, with increased apoptosis i

113 sses the catabolic events that are caused by osteoclastic bone resorption.

114 FK) is, in contrast, a negative regulator of osteoclastic bone resorption.

115 ctor kappaB ligand, an essential mediator of osteoclastic bone resorption.

116 ance between osteoblastic bone formation and osteoclastic bone resorption.

117 s from inflammatory reactions that stimulate osteoclastic bone resorption.

118 xpression of lysosomal enzymes essential for osteoclastic bone resorption.

119 d by osteoblasts and seems to be involved in osteoclastic bone resorption.

120 ance between osteoblastic bone formation and osteoclastic bone resorption.

121 ys its so far uncharacterized action against osteoclastic bone resorption.

122 nhanced expression of cytokines that promote osteoclastic bone resorption.

123 hosphonates and their activity in inhibiting osteoclastic bone resorption.

124 L-6), an inflammatory cytokine implicated in osteoclastic bone resorption.

125 which mediates the subsequent stimulation of osteoclastic bone resorption.

126 nt bone loss because of a marked increase in osteoclastic bone resorption.

127 tastases that are characterized by excessive osteoclastic bone resorption.

128 is the major protease responsible for human osteoclastic bone resorption.

129 Superoxide production contributes to osteoclastic bone resorption.

130 tion and sealing zone formation required for osteoclastic bone resorption.

131 I collagen is necessary for PTH induction of osteoclastic bone resorption.

132 formation of the sealing zone, required for osteoclastic bone resorption.

133 family of diseases characterized by impaired osteoclastic bone resorption.

134 d a rising ambient Ca2+ interact to regulate osteoclastic bone resorption.

135 ast precursors with a subsequent increase in osteoclastic bone resorption.

136 reases in osteoblastic matrix deposition and osteoclastic bone resorption.

137 cathepsin O2 may play a major role in human osteoclastic bone resorption.

138 and metastasize into bone tissue by inducing osteoclastic bone resorption.

139 creases bone mass as the result of defective osteoclastic bone resorption.

140 stic bone formation and indirectly regulates osteoclastic bone resorption.

141 together have established that TSH inhibits osteoclastic bone resorption.

142 ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption.

143 r of NF-kappaB ligand (RANKL), which induces osteoclastic bone resorption.

144 y at all ages examined, indicating defective osteoclastic bone turnover.

145 maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteocla

146 presence of IFN-gamma, and we found that the osteoclastic capacity of CD40L(-/-) T cells could be gre

147 The ADP-ribosyl cyclase activity of osteoclastic CD38 was next demonstrated by its ability t

148 al pathogen, and Escherichia coli LPS induce osteoclastic cell formation from murine leukocytes in th

149 these involve not only the osteoblastic and osteoclastic cell lineages but also other marrow cells,

150 loss and revealed increased numbers of TRAP+ osteoclastic cells lining the alveolar bone surface in S

151 kemia-induced uncoupling of osteoblastic and osteoclastic cells may represent a novel approach to pro

152 al disorganization, the capacity of VCL(-/-) osteoclastic cells to normally phosphorylate c-Src in re

153 The number of differentiated osteoclastic cells was determined after tartrate-resista

154 Oxylipids also induce resorptive osteoclastic cells within the bone environment, raising

155 For osteoclastic cells, cell count and lysate acid phosphata

156 oter to drive expression of rabbit PTP-oc in osteoclastic cells.

157 ation that PTPepsilon is highly expressed in osteoclastic cells.

158 at PKD2 is the main PKD isoform expressed in osteoclastic cells.

159 mune response that disturbs osteoblastic and osteoclastic cellular homeostasis through cytokine produ

160 sponge construct), miR-29 knockdown impaired osteoclastic commitment and migration of pre-osteoclasts

161 astic skeletal metastases with an underlying osteoclastic component.

162 findings were partially explained by higher osteoclastic coverage of the bone-periodontal ligament i

163 bone accumulation by modulating osteoblastic/osteoclastic cross-talk through the direct regulation of

164 deficiency to an osteoblastic rather than an osteoclastic defect.

165 nd indicate that this loss is not limited to osteoclastic degradation.

166 cal TLR5 ligation in vivo provoke homing and osteoclastic development of myeloid cells, which are ass

167 derived preosteoclasts with isoPGE2 enhanced osteoclastic differentiation as evidenced by increased t

168 The enhanced osteoclastic differentiation by isoPGE2 was observed whe

169 Osteoclastic differentiation capacities of bone marrow m

170 egulation of chondrocytic, osteoblastic, and osteoclastic differentiation during skeletal development

171 rom MLO-Y4 cells decreased the capability of osteoclastic differentiation from the cells induced by m

172 ent developments in the area of mediators of osteoclastic differentiation have expanded our knowledge

173 onocyte proliferation but regulated monocyte osteoclastic differentiation in a cell-density dependent

174 e beta-PDGFR, only PDGF-D was able to induce osteoclastic differentiation in vitro, and upregulate th

175 at MB and LB was cultured in osteoblastic or osteoclastic differentiation media.

176 These data suggest that isoPGE2 enhances osteoclastic differentiation of marrow preosteoclasts an

177 ompressive stress regulates osteoblastic and osteoclastic differentiation through osteoblasts in a ma

178 We studied estrogen effects on osteoclastic differentiation using RAW264.7, a murine mo

179 Consistent with these results, osteoclastic differentiation was induced when monocytic

180 The ex vivo suppression capacity of Tregs on osteoclastic differentiation was significantly lower in

181 Both osteoblastic and osteoblast-regulated osteoclastic differentiation were enhanced at 2 g/cm(2).

182 l a new function of PDGF-D as a regulator of osteoclastic differentiation, an activity critical for t

183 significantly inhibited osteoblast-regualted osteoclastic differentiation.

184 eceptor (TweakR) was not responsible for the osteoclastic effect of TWEAK on RAW cells.

185 if) ligand 3 in serum indicated that the pro-osteoclastic effects of the antibiotics are driven by in

186 lencing of CypA verified osteogenic and anti-osteoclastic effects.

187 , CypA dually exerts pro-osteogenic and anti-osteoclastic effects.

188 eocytic sclerostin and up-regulating the pro-osteoclastic factor receptor activator of NF-kappaB liga

189 r survival, invasion and metastasis, and pro-osteoclastic factors.

190 s, pro-osteoclastic gene expressions and pro-osteoclastic function.

191 her increased their RANKL expression and pro-osteoclastic function.

192 vested for comparison of their beta-ARs, pro-osteoclastic gene expressions and pro-osteoclastic funct

193 givalis and Pam2 also up-regulated RANKL and osteoclastic genes in vivo, resulting in an increased nu

194 eoblastic genes was increased, the levels of osteoclastic genes were decreased by loading.

195 c carcinoma characterized by the presence of osteoclastic giant cells mixed with mononuclear cell.

196 ur findings indicate that tamoxifen inhibits osteoclastic HCl transport by binding membrane-associate

197 surfaces showed an osteoblast shift to a pro-osteoclastic-induction phenotype, compared with non-infe

198 tion by a proteasomal inhibitor (PS-341) and osteoclastic inhibition by zoledronic acid (Zol) on the

199 ction of Foxo3 isoform2 that acts as a novel osteoclastic inhibitor in bone remodeling.

200 the current state of pathophysiology of the osteoclastic lesion and outline diagnostic and therapeut

201 through binding to its specific receptor on osteoclastic lineage cells and stimulates osteoclastogen

202 commitment of hemopoietic precursors to the osteoclastic lineage.

203 bone and blocked the elevated expression of osteoclastic marker NFATc1 in bone marrow cells.

204 one formation and by decreased expression of osteoclastic markers and bone resorption activity, as we

205 and greater suppression of osteoblastic and osteoclastic markers than Runx2-II(+/-) mice.

206 al density (BMD), decreased osteoblastic and osteoclastic markers, lower bone formation rates, impair

207 ge and downregulated proinflammatory and pro-osteoclastic markers.

208 Osteoclastic matrix degradation occurs in the extracellu

209 simultaneously ablated the inflammatory, pro-osteoclastic milieu.

210 f breast and skin cancers, are diminished in osteoclastic miR-34a transgenic mice, and can be effecti

211 Osteoclastic miR-34a-overexpressing transgenic mice exhi

212 both in the osteolytic PC3 and osteoblastic/osteoclastic mixed C4-2B cells; while the activation of

213 resulted in the formation of an osteoblastic/osteoclastic mixed tumor with increased osteoclasts surr

214 osteopetrosis due to an intrinsic defect of osteoclastic modelling activity that was confirmed in th

215 ) staining showed that zoledronate decreased osteoclastic numbers and that there was a dose-dependent

216 gated based on phenotypes that are primarily osteoclastic, osteoblastic or mixed.

217 in bone marrow and development of associated osteoclastic osteolysis through cell-cell interactions h

218 knowledge or quantitation of alveolar crest osteoclastic (periodontitis) activity and infiltrate.

219 e resorbing cells in RA exhibit a definitive osteoclastic phenotype, suggesting that pharmacological

220 ssessed whether oxidized lipids regulate the osteoclastic potential of marrow hematopoietic cells.

221 entoblasts participate in the recruitment of osteoclastic precursor cells by up-regulation of chemoki

222 An osteoclastic protein-tyrosine phosphatase (PTP-oc), esse

223 These results indicate that osteoclastic reaction is required even in the osteoblast

224 ed bony EP has increased porosity because of osteoclastic remodeling activity and may be a source of

225 l-mimosine) and 100 ng/ml ANGPTL4 stimulated osteoclastic resorption 2- to 3-fold in assays of lacuna

226 tion and necrosis during acute infection and osteoclastic resorption accompanied by new woven bone fo

227 nd cathepsin K in an in vitro assay of human osteoclastic resorption and an in situ assay of osteocla

228 Microcracks could promote focussed osteoclastic resorption and the formation of resorption

229 wever, aging of bone increased CatK-mediated osteoclastic resorption by approximately 27%, and neglig

230 r attention should be paid to the effects of osteoclastic resorption in designing methods for enhanci

231 Because, in the 5TGM1 model, blockade of osteoclastic resorption in other situations does not dec

232 Bone mass is increased and osteoclastic resorption is decreased in haploinsufficien

233 This study suggests that osteoclastic resorption is the predominant activity in '

234 Increased osteoclastic resorption leads to many bone diseases, inc

235 geneous disorder, characterized by defective osteoclastic resorption of bone that results in increase

236 of bone metastases depends on tumor-induced osteoclastic resorption of bone, which may be inhibited

237 ey regulator of the bone loss that is due to osteoclastic resorption of bone.

238 BR is characterized by osteoclastic resorption of preexisting bone followed by

239 extensively pigmented, there was aggressive osteoclastic resorption of the subchondral plate.

240 es responsible for osteocytic osteolysis and osteoclastic resorption than the WT females.

241 malities of bone remodelling, with increased osteoclastic resorption the primary feature of the disea

242 When studied on resorbable substrates, osteoclastic resorption was suppressed by wortmannin and

243 factors released from the bone matrix during osteoclastic resorption, estrogen deficiency unleashes s

244 a central role of SLP-76/Vav3 association in osteoclastic resorption, retroviral transduction of SLP-

245 e involved in bone remodeling and can induce osteoclastic resorption.

246 d not detect significant effects of MK801 on osteoclastic resorption.

247 se of osteoblastic defects and not increased osteoclastic resorption.

248 A similar condition, feline osteoclastic resorptive lesions (FORL), affects up to 70

249 Osteoclastic responses to TNF-alpha (TNF) challenge in c

250 We attributed this phenotype to osteoclastic sensitization to the receptor activator of

251 The regulation of osteoclastic signaling is incompletely understood, but u

252 Antisense oligonucleotides of Nox 4 reduced osteoclastic superoxide generation as well as resorption

253 steoblastic surface, resorption surface, and osteoclastic surface and a lower mineralizing surface, c

254 g through osteoblastic matrix deposition and osteoclastic tissue resorption and immunomodulation for

255 ted whether transgenic expression of PTP-oc (osteoclastic transmembrane protein-tyrosine phosphatase)

256 A potent and selective inhibitor of the osteoclastic V-H(+)-ATPase, (2Z,4E)-5-(5,6-dichloro-2-in

257 with SB 242784, a specific inhibitor of the osteoclastic V-H+-ATPase, will inhibit arterial calcific

258 reduce bone resorption through inhibition of osteoclastic vacuolar proton pumps.